The Latest Breaking News from Abbott

The U.S. Food and Drug Administration (FDA) in December issued a safety alert urging people with diabetes to stop using select glucose sensors made by Abbott Laboratories’ (NYSE:ABT) Diabetes Care, after the company linked the devices to seven deaths and hundreds of serious injuries.

The sensors provide real-time measurements of sugar levels in the blood, sending that data wirelessly to a device or phone.

For the previous edition of Deal Dispatch, click here.

Plenty of brands have already dropped major Black Friday discounts, and these are items worth shopping right now

Exact Sciences stock rallies as Abbott announces a $21 billion deal to acquire to the molecular diagnostics firm. Here’s why EXAS shares are unlikely to push any higher in 2026.

Rumours fly that Abbott is very close to sealing the deal to acquire cancer treatment champion Exact Sciences.

Abbott Laboratories (NYSE:ABT) agreed on Thursday to acquire cancer screening company Exact Sciences Corp (NASDAQ:EXAS) for $105 per common share, representing a total equity value of approximately $21 billion and an estimated enterprise value of $23 billion.

Hear me out.

Stocks dropped hard last week, but a late-day rally on Friday staved off the worst. The Dow Jones Industrial Average held up the best, only closing down 1.21%. The SP 500 was down 1.63%, but the Nasdaq suffered the most, as it closed down 3.04%. Tech was routed hard as…